{"id":"corvert-ibutilide","safety":{"commonSideEffects":[{"rate":"1.7-3.6","effect":"Ventricular tachycardia (including torsades de pointes)"},{"rate":"3.6","effect":"Headache"},{"rate":"2.2","effect":"Palpitations"},{"rate":"2.0","effect":"Hypotension"},{"rate":"1.9","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2355456","moleculeType":"Small molecule","molecularWeight":"885.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ibutilide works primarily through delayed rectifier potassium channel blockade, which extends the refractory period of cardiac tissue. Additionally, it enhances the inward sodium current during the action potential plateau phase. These combined effects increase the duration of the action potential and refractory period, helping to terminate atrial arrhythmias by increasing the likelihood of successful electrical cardioversion.","oneSentence":"Ibutilide is a Class III antiarrhythmic agent that prolongs the cardiac action potential duration by blocking potassium channels and activating inward sodium current.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:51.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute conversion of atrial fibrillation or atrial flutter to normal sinus rhythm"}]},"trialDetails":[{"nctId":"NCT04675788","phase":"PHASE4","title":"Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening","status":"COMPLETED","sponsor":"Indiana University","startDate":"2021-09-02","conditions":"Long QT Syndrome, Abnormalities, Drug-Induced","enrollment":73},{"nctId":"NCT03834883","phase":"PHASE4","title":"Reducing the Risk of Drug-Induced QT Interval Lengthening in Women","status":"COMPLETED","sponsor":"Indiana University","startDate":"2019-03-26","conditions":"Long QT Syndrome, Abnormalities, Drug-Induced","enrollment":27},{"nctId":"NCT03836092","phase":"","title":"ECGI in Patients With Persistent Atrial Fibrillation","status":"COMPLETED","sponsor":"Pacific Rim Electrophysiology Research Institute","startDate":"2018-02-23","conditions":"Atrial Fibrillation","enrollment":50},{"nctId":"NCT03370536","phase":"NA","title":"ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization","status":"TERMINATED","sponsor":"Vivek Reddy","startDate":"2017-11-01","conditions":"Atrial Fibrillation, Persistent Atrial Fibrillation","enrollment":1},{"nctId":"NCT02513940","phase":"PHASE4","title":"Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes","status":"COMPLETED","sponsor":"Indiana University","startDate":"2016-05","conditions":"Long QT Syndrome","enrollment":14},{"nctId":"NCT01014741","phase":"NA","title":"Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation","status":"COMPLETED","sponsor":"Vivek Reddy","startDate":"2009-10","conditions":"Persistent Atrial Fibrillation","enrollment":200},{"nctId":"NCT01929083","phase":"PHASE2","title":"Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening","status":"COMPLETED","sponsor":"Indiana University","startDate":"2013-04","conditions":"Prolonged QT Interval in EKG and Sudden Death","enrollment":19},{"nctId":"NCT01447862","phase":"PHASE4","title":"Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-10","conditions":"Atrial Fibrillation","enrollment":101},{"nctId":"NCT00589992","phase":"NA","title":"Ibutilide Administration During Pulmonary Vein Ablation","status":"UNKNOWN","sponsor":"Ball Memorial Hospital","startDate":"2007-10","conditions":"Atrial Fibrillation, Pulmonary Vein Ablation","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":387,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Corvert (Ibutilide)","genericName":"Corvert (Ibutilide)","companyName":"Medical University of Vienna","companyId":"medical-university-of-vienna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibutilide is a Class III antiarrhythmic agent that prolongs the cardiac action potential duration by blocking potassium channels and activating inward sodium current. Used for Acute conversion of atrial fibrillation or atrial flutter to normal sinus rhythm.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}